Abstract:
Abstract. Thrombin-activated Fibrinolysis inhibitor (TAFI), participates in the regulation of the balance between coagulation and fibrinolysis. High plasma levels of TAFI may therefore contribute to a hyperfibrinolytic condition and an increased risk of thrombotic disorders. Coronary stenosis is a consequence of the progression of atherosclerotic plaques, which is associated with a violation of fibrinolysis. Thrombin-activated fibrinolysis inhibitor (TAFI) and plasminogen activator 1 inhibitor (PAI-1) are fibrinolysis inhibitors whose levels depend on acquired conditions and polymorphisms. Therefore, our study is aimed at studying the association of TAFI gene polymorphism with the severity of coronary stenosis in patients with stable coronary artery disease (CAD).
The methods that have recently appeared for determining alleles of polymorphic genetic markers using polymerase chain reaction will allow us to assess the genetic risk of developing cardiovascular pathology especially for the purpose of primary prevention of coronary heart disease, as well as to improve new approaches to individualization of therapy as a secondary prevention of the disease.
